MERCK DEVELOPING NEW STABILITY TESTS FOR PRIMAXIN, MEFOXIN
MERCK DEVELOPING NEW STABILITY TESTS FOR PRIMAXIN, MEFOXIN in response to a Dec. 6 FDA warning letter which said that Merck's "failure to conduct reconstitution stability testing for these products is a significant deviation [from current Good Manufacturing Practices] and we are concerned about the absence of such data for products that are currently on the market." The warning letter from FDA's Baltimore district office followed an Oct. 27-Nov. 10, 1993 inspection of Merck's Elkton, Va. manufacturing facility. Primaxin I.V. and I.M. (imipenem/cilastatin sodium) and Mefoxin (cefoxitin sodium) are broad-spectrum injectable antibiotics.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth